However, in our study, the risk of hypoglycemia increased when SGLT2 inhibitors were sequentially added to pre-existing DPP4 inhibitors, which was probably due to a study that permitted insulin and/or sulfonylureas as background anti-diabetes therapy11. This evidence concerns the gene INS and diabetes mellitus.